QMR
VARENICLINE
Created: | 2012-01-19 |
Last modified: | 2014-04-28 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 29 |
Chiral Atom Count | 2 |
Bond Count | 32 |
Aromatic Bond Count | 11 |
Chemical Component Summary | |
---|---|
Name | VARENICLINE |
Systematic Name (OpenEye OEToolkits) | n/a |
Formula | C13 H13 N3 |
Molecular Weight | 211.262 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | n1c2cc3c(cc2ncc1)C4CNCC3C4 |
SMILES | CACTVS | 3.370 | C1NC[CH]2C[CH]1c3cc4nccnc4cc23 |
SMILES | OpenEye OEToolkits | 1.7.6 | c1cnc2cc3c(cc2n1)C4CC3CNC4 |
Canonical SMILES | CACTVS | 3.370 | C1NC[C@@H]2C[C@H]1c3cc4nccnc4cc23 |
Canonical SMILES | OpenEye OEToolkits | 1.7.6 | c1cnc2cc3c(cc2n1)[C@@H]4C[C@H]3CNC4 |
InChI | InChI | 1.03 | InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/t8-,9+ |
InChIKey | InChI | 1.03 | JQSHBVHOMNKWFT-DTORHVGOSA-N |
Drug Info: DrugBank
DrugBank ID | DB01273 |
---|---|
Name | Varenicline |
Groups |
|
Description | Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced. |
Synonyms |
|
Brand Names |
|
Indication | For use as an aid in smoking cessation. Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.[L38954] |
Categories |
|
ATC-Code |
|
CAS number | 249296-44-4 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Neuronal acetylcholine receptor subunit alpha-4 | MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNK... | unknown | partial agonist |
Neuronal acetylcholine receptor subunit alpha-7 | MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQP... | unknown | agonist |
Neuronal acetylcholine receptor subunit alpha-3 | MGSGPLSLPLALSPPRLLLLLLLSLLPVARASEAEHRLFERLFEDYNEII... | unknown | partial agonist |
Neuronal acetylcholine receptor subunit alpha-6 | MLTSKGQGFLHGGLCLWLCVFTPFFKGCVGCATEERLFHKLFSHYNQFIR... | unknown | partial agonist |
Neuronal acetylcholine receptor subunit beta-2 | MARRCGPVALLLGFGLLRLCSGVWGTDTEERLVEHLLDPSRYNKLIRPAT... | unknown | partial agonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 5310966 |
ChEMBL | CHEMBL1076903 |
ChEBI | CHEBI:84500 |